NCT05640778View on ClinicalTrials.gov

Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 1, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2025

Conditions
Luminal B/HER2-negative Breast Cancer
Interventions
DRUG

Dalpiciclib combined with aromatase inhibitors

Dalpiciclib combined with letrozole or anastrozole

Trial Locations (1)

Unknown

RECRUITING

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

Sponsors
All Listed Sponsors
collaborator

GeneCast Biotechnology Co., Ltd.

INDUSTRY

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT05640778 - Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER) | Biotech Hunter | Biotech Hunter